Baker Bros. Advisors Adds $29M in Enliven Therapeutics, Inc. ($ELVN)
Key Points
- Baker Bros. Advisors changed its Enliven Therapeutics, Inc. ($ELVN) stake by 233.5% last quarter, boosting to 905,191 shares worth $41.76 million.
- Wall Street's consensus rating on $ELVN is Strong Buy and an average price target of $60.11.
- $ELVN last traded around $46.13.
Baker Bros. Advisors increased its position in Enliven Therapeutics, Inc. ($ELVN) by 233.5% during the most recent quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 905,191 shares of Enliven Therapeutics, Inc. after buying 633,785 shares during the quarter. Baker Bros. Advisors's holdings in Enliven Therapeutics, Inc. were worth $41.76 million as of its most recent filing.
Enliven Therapeutics, Inc. ($ELVN) Stock
Enliven Therapeutics, Inc. Earnings
Analysts Set New Price Targets
About Enliven Therapeutics, Inc.
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 mutant tumors. The company was founded in 2019 and is headquartered in Boulder, Colorado.
See Also
This instant news alert was generated by automated narrative technology and financial data from Trueearnings and public regulatory filings. It is for informational purposes only and is not financial advice.